Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine
tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under
fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence
crossover design.